264 related articles for article (PubMed ID: 10913187)
1. Transcriptional scaffold: CIITA interacts with NF-Y, RFX, and CREB to cause stereospecific regulation of the class II major histocompatibility complex promoter.
Zhu XS; Linhoff MW; Li G; Chin KC; Maity SN; Ting JP
Mol Cell Biol; 2000 Aug; 20(16):6051-61. PubMed ID: 10913187
[TBL] [Abstract][Full Text] [Related]
2. CREB and phospho-CREB interact with RFX5 and CIITA to regulate MHC class II genes.
Lochamy J; Rogers EM; Boss JM
Mol Immunol; 2007 Feb; 44(5):837-47. PubMed ID: 16730065
[TBL] [Abstract][Full Text] [Related]
3. Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen Inhibits Major Histocompatibility Complex Class II Expression by Disrupting Enhanceosome Assembly through Binding with the Regulatory Factor X Complex.
Thakker S; Purushothaman P; Gupta N; Challa S; Cai Q; Verma SC
J Virol; 2015 May; 89(10):5536-56. PubMed ID: 25740990
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase 1/mSin3A disrupts gamma interferon-induced CIITA function and major histocompatibility complex class II enhanceosome formation.
Zika E; Greer SF; Zhu XS; Ting JP
Mol Cell Biol; 2003 May; 23(9):3091-102. PubMed ID: 12697811
[TBL] [Abstract][Full Text] [Related]
5. Assembly of major histocompatibility complex (MHC) class II transcription factors: association and promoter recognition of RFX proteins.
Burd AL; Ingraham RH; Goldrick SE; Kroe RR; Crute JJ; Grygon CA
Biochemistry; 2004 Oct; 43(40):12750-60. PubMed ID: 15461447
[TBL] [Abstract][Full Text] [Related]
6. Dissection of functional NF-Y-RFX cooperative interactions on the MHC class II Ea promoter.
Caretti G; Cocchiarella F; Sidoli C; Villard J; Peretti M; Reith W; Mantovani R
J Mol Biol; 2000 Sep; 302(3):539-52. PubMed ID: 10986117
[TBL] [Abstract][Full Text] [Related]
7. A functionally essential domain of RFX5 mediates activation of major histocompatibility complex class II promoters by promoting cooperative binding between RFX and NF-Y.
Villard J; Peretti M; Masternak K; Barras E; Caretti G; Mantovani R; Reith W
Mol Cell Biol; 2000 May; 20(10):3364-76. PubMed ID: 10779326
[TBL] [Abstract][Full Text] [Related]
8. CIITA leucine-rich repeats control nuclear localization, in vivo recruitment to the major histocompatibility complex (MHC) class II enhanceosome, and MHC class II gene transactivation.
Hake SB; Masternak K; Kammerbauer C; Janzen C; Reith W; Steimle V
Mol Cell Biol; 2000 Oct; 20(20):7716-25. PubMed ID: 11003667
[TBL] [Abstract][Full Text] [Related]
9. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients.
Masternak K; Barras E; Zufferey M; Conrad B; Corthals G; Aebersold R; Sanchez JC; Hochstrasser DF; Mach B; Reith W
Nat Genet; 1998 Nov; 20(3):273-7. PubMed ID: 9806546
[TBL] [Abstract][Full Text] [Related]
10. Transcriptional regulation of the MHC class II trans-activator (CIITA) promoter III: identification of a novel regulatory region in the 5'-untranslated region and an important role for cAMP-responsive element binding protein 1 and activating transcription factor-1 in CIITA-promoter III transcriptional activation in B lymphocytes.
van der Stoep N; Quinten E; van den Elsen PJ
J Immunol; 2002 Nov; 169(9):5061-71. PubMed ID: 12391222
[TBL] [Abstract][Full Text] [Related]
11. CIITA-induced occupation of MHC class II promoters is independent of the cooperative stabilization of the promoter-bound multi-protein complexes.
Villard J; Muhlethaler-Mottet A; Bontron S; Mach B; Reith W
Int Immunol; 1999 Mar; 11(3):461-9. PubMed ID: 10221658
[TBL] [Abstract][Full Text] [Related]
12. Novel mutations in the RFXANK gene: RFX complex containing in-vitro-generated RFXANK mutant binds the promoter without transactivating MHC II.
Wiszniewski W; Fondaneche MC; Louise-Plence P; Prochnicka-Chalufour A; Selz F; Picard C; Le Deist F; Eliaou JF; Fischer A; Lisowska-Grospierre B
Immunogenetics; 2003 Feb; 54(11):747-55. PubMed ID: 12618906
[TBL] [Abstract][Full Text] [Related]
13. The S box of major histocompatibility complex class II promoters is a key determinant for recruitment of the transcriptional co-activator CIITA.
Muhlethaler-Mottet A; Krawczyk M; Masternak K; Spilianakis C; Kretsovali A; Papamatheakis J; Reith W
J Biol Chem; 2004 Sep; 279(39):40529-35. PubMed ID: 15271997
[TBL] [Abstract][Full Text] [Related]
14. Promoter-specific functions of CIITA and the MHC class II enhanceosome in transcriptional activation.
Masternak K; Reith W
EMBO J; 2002 Mar; 21(6):1379-88. PubMed ID: 11889043
[TBL] [Abstract][Full Text] [Related]
15. MHC class II enhanceosome: how is the class II transactivator recruited to DNA-bound activators?
Jabrane-Ferrat N; Nekrep N; Tosi G; Esserman L; Peterlin BM
Int Immunol; 2003 Apr; 15(4):467-75. PubMed ID: 12663676
[TBL] [Abstract][Full Text] [Related]
16. Major histocompatibility complex class II transcriptional platform: assembly of nuclear factor Y and regulatory factor X (RFX) on DNA requires RFX5 dimers.
Jabrane-Ferrat N; Nekrep N; Tosi G; Esserman LJ; Peterlin BM
Mol Cell Biol; 2002 Aug; 22(15):5616-25. PubMed ID: 12101253
[TBL] [Abstract][Full Text] [Related]
17. Specific complex formation between the type II bare lymphocyte syndrome-associated transactivators CIITA and RFX5.
Scholl T; Mahanta SK; Strominger JL
Proc Natl Acad Sci U S A; 1997 Jun; 94(12):6330-4. PubMed ID: 9177217
[TBL] [Abstract][Full Text] [Related]
18. Function of major histocompatibility complex class II promoters requires cooperative binding between factors RFX and NF-Y.
Reith W; Siegrist CA; Durand B; Barras E; Mach B
Proc Natl Acad Sci U S A; 1994 Jan; 91(2):554-8. PubMed ID: 8290561
[TBL] [Abstract][Full Text] [Related]
19. Associations and interactions between bare lymphocyte syndrome factors.
DeSandro AM; Nagarajan UM; Boss JM
Mol Cell Biol; 2000 Sep; 20(17):6587-99. PubMed ID: 10938133
[TBL] [Abstract][Full Text] [Related]
20. Long distance control of MHC class II expression by multiple distal enhancers regulated by regulatory factor X complex and CIITA.
Krawczyk M; Peyraud N; Rybtsova N; Masternak K; Bucher P; Barras E; Reith W
J Immunol; 2004 Nov; 173(10):6200-10. PubMed ID: 15528357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
